B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS. (5th April 2022) - Mateos, M; Hari, P; Bahlis, N; Chari, A; van de Donk, NWCJ; Dholaria, B; Garfall, AL; Goldschmidt, H; Kortüm, KM; Krishnan, A; Martin, T; Morillo, D; et al.